Erik Fink Eriksen
Position: Professor II
Phone: +47 228 94187
Email:
 

Publications 2017

Garcia Lopez M, Bønaa KH, Ebbing M, Eriksen EF, Gjesdal CG, Nygård O, Tell GS, Ueland PM, Meyer HE (2017)
B Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-Up of Two Large Randomized Controlled Trials
J Bone Miner Res, 32 (10), 1981-1989
PubMed 28574605

Gulseth HL, Wium C, Angel K, Eriksen EF, Birkeland KI (2017)
Effects of Vitamin D Supplementation on Insulin Sensitivity and Insulin Secretion in Subjects With Type 2 Diabetes and Vitamin D Deficiency: A Randomized Controlled Trial
Diabetes Care, 40 (7), 872-878
PubMed 28468770

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017)
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG
J Bone Oncol, 7, 1-12
PubMed 28413771

Holmøy T, Lindstrøm JC, Eriksen EF, Steffensen LH, Kampman MT (2017)
High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial
BMC Neurol, 17 (1), 67
PubMed 28376767

Osima M, Kral R, Borgen TT, Høgestøl IK, Joakimsen RM, Eriksen EF, Bjørnerem Å (2017)
Women with type 2 diabetes mellitus have lower cortical porosity of the proximal femoral shaft using low-resolution CT than nondiabetic women, and increasing glucose is associated with reduced cortical porosity
Bone, 97, 252-260
PubMed 28161589

Shabestari M, Eriksen EF, Paschalis EP, Roschger P, Gamsjaeger S, Klaushofer K, Berzlanovich A, Nogues X, Puig L, Diez-Perez A (2017)
Presence of pyrophosphate in bone from an atypical femoral fracture site: A case report
Bone Rep, 6, 81-86
PubMed 28377987

Sosa DD, Eriksen EF (2017)
Reduced Bone Material Strength is Associated with Increased Risk and Severity of Osteoporotic Fractures. An Impact Microindentation Study
Calcif Tissue Int, 101 (1), 34-42
PubMed 28246929

Steineger J, Merckoll E, Slåstad JM, Eriksen EF, Heimdal K, Dheyauldeen S (2017)
Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report
Laryngoscope (in press)
PubMed 28671294

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017)
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Bone, 105, 11-17
PubMed 28789921

Aass C, Norheim I, Eriksen EF, Børnick EC, Thorsby PM, Pepaj M (2017)
Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy
PLoS One, 12 (4), e0175274
PubMed 28419103

Publications 2016

Astor MC, Løvås K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebø BG, Svartberg J, Husebye ES (2016)
Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway
J Clin Endocrinol Metab, 101 (8), 3045-53
PubMed 27186861

Eriksen EF, Brown JP (2016)
Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics"
Bone, 89, 75-76
PubMed 27142587

Eriksen EF, Brown JP (2016)
Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics
Bone, 86, 139-42
PubMed 26944033

Paschalis EP, Gamsjaeger S, Hassler N, Fahrleitner-Pammer A, Dobnig H, Stepan JJ, Pavo I, Eriksen EF, Klaushofer K (2016)
Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality
Bone, 95, 41-46
PubMed 27826025

Simonsen CS, Celius EG, Brunborg C, Tallaksen C, Eriksen EF, Holmøy T, Moen SM (2016)
Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
BMC Neurol, 16 (1), 252
PubMed 27919248

Aasarød KM, Ramezanzadehkoldeh M, Shabestari M, Mosti MP, Stunes AK, Reseland JE, Beisvag V, Eriksen EF, Sandvik AK, Erben RG, Schüler C, Boyce M, Skallerud BH, Syversen U, Fossmark R (2016)
Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice
J Endocrinol, 230 (2), 251-62
PubMed 27325243

Publications 2015

Eriksen EF (2015)
[Re: Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates]
Tidsskr Nor Laegeforen, 135 (10), 921
PubMed 26037748

Eriksen EF (2015)
Treatment of bone marrow lesions (bone marrow edema)
Bonekey Rep, 4, 755
PubMed 26644910

Paschalis EP, Fratzl P, Gamsjaeger S, Hassler N, Brozek W, Eriksen EF, Rauch F, Glorieux FH, Shane E, Dempster D, Cohen A, Recker R, Klaushofer K (2015)
Aging Versus Postmenopausal Osteoporosis: Bone Composition and Maturation Kinetics at Actively-Forming Trabecular Surfaces of Female Subjects Aged 1 to 84 Years
J Bone Miner Res, 31 (2), 347-57
PubMed 26308158

Shigdel R, Osima M, Ahmed LA, Joakimsen RM, Eriksen EF, Zebaze R, Bjørnerem Å (2015)
Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures
Bone, 81, 1-6
PubMed 26112819

Shigdel R, Osima M, Lukic M, Ahmed LA, Joakimsen RM, Eriksen EF, Bjørnerem Å (2015)
Determinants of Transitional Zone Area and Porosity of the Proximal Femur Quantified In Vivo in Postmenopausal Women
J Bone Miner Res, 31 (4), 758-66
PubMed 26588794

Aass C, Norheim I, Eriksen EF, Thorsby PM, Pepaj M (2015)
Single unit filter-aided method for fast proteomic analysis of tear fluid
Anal Biochem, 480, 1-5
PubMed 25862084

Publications 2014

Dahl K, Ahmed LA, Joakimsen RM, Jørgensen L, Eggen AE, Eriksen EF, Bjørnerem Å (2014)
High-sensitivity C-reactive protein is an independent risk factor for non-vertebral fractures in women and men: The Tromsø Study
Bone, 72, 65-70
PubMed 25460573

Eriksen EF (2014)
Commentary on sclerostin deficiency is linked to altered bone composition
J Bone Miner Res, 29 (10), 2141-3
PubMed 25158054

Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014)
Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis
Bone, 67, 246-56
PubMed 25053463

Wekre LL, Kjensli A, Aasand K, Falch JA, Eriksen EF (2014)
Spinal deformities and lung function in adults with osteogenesis imperfecta
Clin Respir J, 8 (4), 437-43
PubMed 24308436

Publications 2013

Eriksen EF, Díez-Pérez A, Boonen S (2013)
Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review
Bone, 58, 126-35
PubMed 24120384

Eriksen EF, Halse J, Moen MH (2013)
New developments in the treatment of osteoporosis
Acta Obstet Gynecol Scand, 92 (6), 620-36
PubMed 22646526

Hammerstad SS, Norheim I, Paulsen T, Amlie LM, Eriksen EF (2013)
Excessive decrease in serum magnesium after total thyroidectomy for Graves' disease is related to development of permanent hypocalcemia
World J Surg, 37 (2), 369-75
PubMed 23188529

Hewitt S, Søvik TT, Aasheim ET, Kristinsson J, Jahnsen J, Birketvedt GS, Bøhmer T, Eriksen EF, Mala T (2013)
Secondary hyperparathyroidism, vitamin D sufficiency, and serum calcium 5 years after gastric bypass and duodenal switch
Obes Surg, 23 (3), 384-90
PubMed 23015268

Misof BM, Roschger P, Gabriel D, Paschalis EP, Eriksen EF, Recker RR, Gasser JA, Klaushofer K (2013)
Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort
J Bone Miner Res, 28 (3), 442-8
PubMed 23044788

Wium C, Gulseth HL, Eriksen EF, Birkeland KI (2013)
Characteristics of glucose metabolism in Nordic and South Asian subjects with type 2 diabetes
PLoS One, 8 (12), e83983
PubMed 24391858

Publications 2012

Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F (2012)
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective
J Bone Miner Res, 27 (5), 963-74
PubMed 22467094

Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E (2012)
Fracture risk and zoledronic acid therapy in men with osteoporosis
N Engl J Med, 367 (18), 1714-23
PubMed 23113482

Eriksen EF (2012)
Treatment of osteopenia
Rev Endocr Metab Disord, 13 (3), 209-23
PubMed 21710179

Eriksen EF, Halse J (2012)
[When should bisphosphonate treatment be discontinued?]
Tidsskr Nor Laegeforen, 132 (14), 1630-2
PubMed 22875131

Moen SM, Celius EG, Sandvik L, Brustad M, Nordsletten L, Eriksen EF, Holmøy T (2012)
Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study
PLoS One, 7 (9), e45703
PubMed 23029191

Publications 2011

Bøhmer T, Eriksen EF (2011)
[Something to learn from--something to learn more from?]
Tidsskr Nor Laegeforen, 131 (22), 2221; author reply 2221
PubMed 22085940

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011)
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
J Bone Miner Res, 26 (3), 503-11
PubMed 20814967

Eriksen EF, Ringe JD (2011)
Bone marrow lesions: a universal bone response to injury?
Rheumatol Int, 32 (3), 575-84
PubMed 21901347

Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP (2011)
Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid
J Bone Miner Res, 26 (1), 12-8
PubMed 20645415

Stunes AK, Westbroek I, Gustafsson BI, Fossmark R, Waarsing JH, Eriksen EF, Petzold C, Reseland JE, Syversen U (2011)
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
BMC Endocr Disord, 11, 11
PubMed 21615901

Syversen U, Halse JI, Geisler J, Eriksen EF (2011)
[Denosumab for treatment of postmenopausal osteoporosis]
Tidsskr Nor Laegeforen, 131 (19), 1893-6
PubMed 21984295

Wekre LL, Eriksen EF, Falch JA (2011)
Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta
Arch Osteoporos, 6, 31-8
PubMed 22207876

Publications 2010

Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW (2010)
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older
J Am Geriatr Soc, 58 (2), 292-9
PubMed 20070415

Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010)
Potential mediators of the mortality reduction with zoledronic acid after hip fracture
J Bone Miner Res, 25 (1), 91-7
PubMed 19580467

Eriksen EF (2010)
Cellular mechanisms of bone remodeling
Rev Endocr Metab Disord, 11 (4), 219-27
PubMed 21188536

Publications 2009

Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R, HORIZON-PFT Research Group (2009)
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis
J Bone Miner Res, 24 (9), 1544-51
PubMed 19338427

Eriksen EF (2009)
[Osteonecrosis of the jaw]
Ugeskr Laeger, 171 (8), 629; author reply 629
PubMed 19291862

Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009)
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture
J Bone Miner Res, 24 (7), 1308-13
PubMed 19257818

Publications 2008

Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008)
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Kidney Int, 74 (5), 641-8
PubMed 18509324

Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group (2008)
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial
J Am Dent Assoc, 139 (1), 32-40
PubMed 18167382

Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008)
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure
J Bone Miner Res, 23 (1), 6-16
PubMed 17892374

Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008)
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
Bone, 42 (5), 841-7
PubMed 18314405

Publications 2007

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
N Engl J Med, 356 (18), 1809-22
PubMed 17476007

Eriksen EF, Eghbali-Fatourechi GZ, Khosla S (2007)
Remodeling and vascular spaces in bone
J Bone Miner Res, 22 (1), 1-6
PubMed 17040170

Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR (2007)
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate
J Bone Miner Res, 22 (1), 142-8
PubMed 17032148

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial (2007)
Zoledronic acid and clinical fractures and mortality after hip fracture
N Engl J Med, 357 (18), 1799-809
PubMed 17878149

Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA (2007)
Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006
Crit Rev Oncol Hematol, 62 (2), 148-52
PubMed 17336086

Publications 2006

Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF (2006)
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis
J Bone Miner Res, 21 (6), 855-64
PubMed 16753016

Publications 2005

Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
J Bone Miner Res, 20 (7), 1244-53
PubMed 15940379

Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L (2005)
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study
J Bone Miner Res, 20 (9), 1548-61
PubMed 16059627

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005)
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial
J Bone Miner Res, 20 (11), 1905-11
PubMed 16234962

Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005)
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy
J Clin Endocrinol Metab, 90 (7), 3970-7
PubMed 15840739

McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005)
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
Arch Intern Med, 165 (15), 1762-8
PubMed 16087825

Paschalis EP, Glass EV, Donley DW, Eriksen EF (2005)
Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial
J Clin Endocrinol Metab, 90 (8), 4644-9
PubMed 15914535

Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005)
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women
Bone, 36 (6), 948-58
PubMed 15878318

Publications 2004

Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L (2004)
Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma
Haematologica, 89 (5), 567-77
PubMed 15136220

Eriksen EF, Robins DA (2004)
Teriparatide: A bone formation treatment for osteoporosis
Drugs Today (Barc), 40 (11), 935-48
PubMed 15645006

Glerup H, Eriksen EF (2004)
[D-vitamin: old paradoxes and new perspectives]
Ugeskr Laeger, 166 (1-2), 36-40
PubMed 14752991

Lind PM, Eriksen EF, Lind L, Orberg J, Sahlin L (2004)
Estrogen supplementation modulates effects of the endocrine disrupting pollutant PCB126 in rat bone and uterus: diverging effects in ovariectomized and intact animals
Toxicology, 199 (2-3), 129-36
PubMed 15147787

Publications 2003

Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L (2003)
Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy
Br J Haematol, 120 (2), 235-42
PubMed 12542480

Andersen H, Jensen ON, Moiseeva EP, Eriksen EF (2003)
A proteome study of secreted prostatic factors affecting osteoblastic activity: galectin-1 is involved in differentiation of human bone marrow stromal cells
J Bone Miner Res, 18 (2), 195-203
PubMed 12568396

Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003)
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
J Bone Miner Res, 18 (11), 1932-41
PubMed 14606504

Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF (2003)
Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis
Bone, 32 (3), 297-310
PubMed 12667558

Publications 2002

Eriksen EF (2002)
Primary hyperparathyroidism: lessons from bone histomorphometry
J Bone Miner Res, 17 Suppl 2, N95-7
PubMed 12412784

Eriksen EF, Glerup H (2002)
Vitamin D deficiency and aging: implications for general health and osteoporosis
Biogerontology, 3 (1-2), 73-7
PubMed 12014847

Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF (2002)
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures
J Bone Miner Res, 17 (7), 1245-55
PubMed 12096838

Publications 2001

Jørgensen NR, Henriksen Z, Sørensen OH, Eriksen EF, Civitelli R, Steinberg TH (2001)
Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors
J Biol Chem, 277 (9), 7574-80
PubMed 11756404